Sumitomo Pharma Co Ltd 2017 AR2
The report outlines Sumitomo Dainippon Pharma Co., Ltd.'s financial and sustainability performance for fiscal 2016. The company achieved record-high net sales of 411.6 billion yen and operating income of 52.8 billion yen, driven by strong sales of LATUDA in North America. Key highlights include strategic acquisitions of Cynapsus Therapeutics and Tolero Pharmaceuticals to enhance the psychiatry, neurology, and oncology pipelines. On the sustainability front, the company promoted work-life balance through its 'Good Daddy Leave' system and advanced global health initiatives like 'Access Accelerated' and maternal health programs in Cambodia.
Company: Sumitomo Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2017
Type: AR2
Pages: 102
Sumitomo Pharma Co Ltd
Annual Report
The report outlines Sumitomo Dainippon Pharma Co., Ltd.'s financial and sustainability performance for fiscal 2016. The company achieved record-high net sales of 411.6 billion yen and operating income of 52.8 billion yen, driven by strong sales of LATUDA in North America. Key highlights include strategic acquisitions of Cynapsus Therapeutics and Tolero Pharmaceuticals to enhance the psychiatry, neurology, and oncology pipelines. On the sustainability front, the company promoted work-life balance through its 'Good Daddy Leave' system and advanced global health initiatives like 'Access Accelerated' and maternal health programs in Cambodia.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women in Management
Employees